A SENSITIVE ANTIVIRAL NEUTRALIZATION BIOASSAY FOR MEASURING ANTIBODIES TO INTERFERONS

被引:31
作者
HANSEN, MB [1 ]
ROSS, C [1 ]
BERG, K [1 ]
机构
[1] UNIV COPENHAGEN, INST MED MICROBIOL, INTERFERON LAB, JULIANE MARIES VEJ 22, DK-2100 COPENHAGEN, DENMARK
关键词
Antibody to interferon; Antiviral neutralization bioassay; Microculture tetrazolium assay; MTT;
D O I
10.1016/0022-1759(90)90074-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An improved bioassay for measuring neutralizing antibodies to interferons (IFN) is described. The assay is based upon an objective and precise quantification of the viral cytophathic effect. This effect is measured via the dehydrogenase-system in cells, and quantified spectrophotometrically. Virus-infected cells, in contrast to non-infected cells, possess low enzyme activity resulting in low OD signals. This fall in OD can be prevented by the addition of a small, but fixed amount of IFN before the addition of virus. Anti-IFN sera will neutralize the protective effect of IFN. This effect can be quantified by measurement of the reduction in the OD signals. Antibodies to recombinant IFN were found to cross-react with human leukocyte IFN although to a ten-fold lower degree. The assay requires no expensive reagents, it is performed in 96-well microtrays and the results can be measured in an ordinary ELISA scanner. The assay is highly reproducible, yielding inter- and intra-assay variability of less than 10%. The sensitivity is much higher than that reported previously for the CPE technique and that of ELISA techniques. © 1990.
引用
收藏
页码:241 / 248
页数:8
相关论文
共 16 条
[1]   IDENTIFICATION, PRODUCTION, AND CHARACTERIZATION OF MURINE MONOCLONAL-ANTIBODY (LO-22) RECOGNIZING 12 NATIVE SPECIES OF HUMAN ALPHA INTERFERON [J].
BERG, K .
JOURNAL OF INTERFERON RESEARCH, 1984, 4 (04) :481-491
[2]  
BERG K, 1982, ACTA PATH MICRO IM C, P1
[3]  
BERG K, 1988, J INTERFERON RES S, V1, P67
[4]   RECOMBINANT INTERFERON ALFA-2A IN METASTATIC RENAL-CELL CARCINOMA - ASSESSMENT OF ANTITUMOR-ACTIVITY AND ANTI-INTERFERON ANTIBODY-FORMATION [J].
FIGLIN, RA ;
DEKERNION, JB ;
MUKAMEL, E ;
PALLERONI, AV ;
ITRI, LM ;
SARNA, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1604-1610
[5]  
FIGLIN RA, 1988, SEMIN HEMATOL, V25, P9
[6]  
FINTER NB, 1984, INTERFERON, V4, P1
[7]   APPLICATION OF AN OBJECTIVE BIOLOGICAL ASSAY OF HUMAN INTERFERONS TO CLINICAL SPECIMENS AND A SURVEY OF A NORMAL POPULATION [J].
FORTI, RL ;
MOLDOVAN, RA ;
MITCHELL, WM ;
CALLICOAT, P ;
SCHUFFMAN, SS ;
DAVIES, HA ;
SMITH, DM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 21 (05) :689-693
[8]   TREATMENT WITH NATURAL HUMAN INTERFERON ALPHA OF A CML-PATIENT WITH ANTIBODIES TO RECOMBINANT INTERFERON ALPHA-2B [J].
FREUND, M ;
VONWUSSOW, P ;
KNUVERHOPF, J ;
MOHR, H ;
POHL, U ;
EXERIEDE, G ;
LINK, H ;
WILKE, HJ ;
POLIWODA, H .
BLUT, 1988, 57 (05) :311-315
[9]  
GROSSBERG SE, 1984, INTERFERON, V1, P189
[10]   RE-EXAMINATION AND FURTHER DEVELOPMENT OF A PRECISE AND RAPID DYE METHOD FOR MEASURING CELL-GROWTH CELL KILL [J].
HANSEN, MB ;
NIELSEN, SE ;
BERG, K .
JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 119 (02) :203-210